Key highlights
07 July 2023 – 1 mins read
LinkedIn
Twitter
Facebook
Primary Biliary Cholangitis (PBC): Looking Beyond the Liver
“Symptom burden is the main issue for the patient.”– Professor Andreas Kremer, Hepatologist of the University of Zurich Hospital
Explore more by category
Showing: 1 – 5 of 96 stories
10 November 2023 – 2 mins read
Ipsen’s mission to accelerate innovation in oncology
The outputs from the European Society of Medical Oncology (ESMO) Congress this year encompassed several important new data announcements, highlighting key advances in the development of therapies for people living with cancer. However, cancer remains a formidable global health challenge,…
10 November 2023 – 1 mins read
Examining the European Pharma legislation: EFPIA publishes the Dolon Report
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation…
03 November 2023 – 0 mins read
31 October 2023 – 2 mins read
Ipsen stands together to make innovation in rare disease happen
Developing innovation for people living with rare diseases is uniquely challenging. It requires all the different pieces of the puzzle– clinical viability, economic viability and the policy environment— to come together before innovation can reach patients.
31 October 2023 – 2 mins read
Innovating for people living with primary biliary cholangitis
At Ipsen we have been focused on developing new and innovative treatments for rare diseases for many years in endocrinology, rare bone disease and more recently in rare liver disease. This focus continues to be a core part of our…
